HER2-Positive Breast Cancer

HER2-positive breast cancer is a type of breast cancer where the cancer cells have too much of a protein called human epidermal growth factor receptor 2 (HER2). This protein helps cells grow, divide, and repair themselves. When there is too much HER2, the cancer cells tend to grow and spread more quickly. About 1 in 5 breast cancers are HER2-positive.

What is HER2-Positive Breast Cancer?

HER2-positive breast cancer is a specific type of breast cancer characterized by an excess of the human epidermal growth factor receptor 2 (HER2) protein on the surface of cancer cells. This protein plays a crucial role in cell growth and division. Having too much HER2 means the cancer cells can grow and spread more aggressively than other types of breast cancer.

The HER2 protein acts like a growth signal receiver for cells. Normally, it helps control how healthy breast cells grow, divide, and repair themselves. However, in HER2-positive breast cancer, the cancer cells have too many HER2 receptors, making them highly sensitive to growth signals. This overabundance of HER2 protein leads to uncontrolled cell growth and division, which can make the cancer more aggressive. Historically, HER2-positive breast cancers were associated with a poorer outlook. However, significant advancements in targeted therapies have dramatically improved outcomes for people with this type of cancer. According to MedlinePlus and Mayo Clinic, approximately 15% to 20% of all breast cancers are found to be HER2-positive. Identifying the HER2 status is a critical step in diagnosing breast cancer, as it directly influences the treatment plan.

Symptoms

The symptoms of HER2-positive breast cancer are generally similar to those of other types of breast cancer and do not have unique signs specific to its HER2 status. The most common symptom is a new lump or mass in the breast, but other changes can also signal a potential problem that requires medical attention.

Many people discover a breast lump themselves, often during a self-exam or by accident. This lump might feel firm or thick and could be painless, though some people experience tenderness or pain. It's important to remember that not all breast lumps are cancerous, but any new lump should be checked by a doctor. Other potential symptoms of breast cancer, regardless of HER2 status, include: * Changes in the size or shape of the breast. * Skin changes on the breast, such as dimpling, puckering, redness, scaling, or thickening. * Nipple changes, including a nipple that turns inward (inversion), redness, scaling, or discharge other than breast milk. * Swelling of all or part of the breast, even if no distinct lump is felt. * Pain in any area of the breast or nipple that does not go away. Because HER2-positive breast cancer can be more aggressive, it's especially important to report any of these symptoms to a healthcare provider promptly. Early detection remains a key factor in successful treatment.

Causes & risk factors

The exact cause of HER2-positive breast cancer is not fully understood, but it is not directly inherited from parents. Instead, HER2-positive status refers to a characteristic of the cancer cells themselves, indicating how they behave. The general risk factors for developing breast cancer also apply to HER2-positive breast cancer.

HER2-positive breast cancer develops when cells in the breast begin to grow abnormally and acquire too many copies of the HER2 gene, or produce too much of the HER2 protein. This genetic change usually happens during a person's lifetime and is not something they are born with. It is not considered an inherited condition. Risk factors for breast cancer in general, as outlined by MedlinePlus and Mayo Clinic, include: * **Age:** The risk of breast cancer increases with age, especially after age 50. * **Family history:** Having close relatives (mother, sister, daughter) who have had breast cancer, particularly at a young age. * **Genetic mutations:** Inheriting certain gene mutations, such as BRCA1 and BRCA2, significantly increases breast cancer risk, though these genes are not directly related to HER2 status. * **Obesity:** Being overweight or obese, especially after menopause. * **Alcohol consumption:** Drinking alcohol can increase risk. * **Radiation exposure:** Exposure to radiation therapy to the chest, particularly at a young age. * **Hormone therapy:** Using combined hormone therapy (estrogen and progestin) after menopause. * **Dense breast tissue:** Having dense breasts can make it harder to detect tumors on mammograms. It's important to understand that while these factors increase the general risk of breast cancer, they do not specifically cause a cancer to become HER2-positive. The HER2 status is determined by the specific genetic makeup of the tumor cells once cancer develops.

How it's diagnosed

Diagnosing HER2-positive breast cancer involves taking a tissue sample (biopsy) from the suspicious area in the breast. This tissue is then sent to a laboratory for specialized tests to determine if the cancer cells have an excess of the HER2 protein or too many copies of the HER2 gene, which confirms the HER2-positive status.

The diagnostic process typically begins with imaging tests, such as a mammogram, ultrasound, or MRI, if a lump or other abnormality is found. If these tests suggest cancer, a biopsy is performed. During a biopsy, a small piece of breast tissue is removed, usually with a needle, and then examined under a microscope. To determine HER2 status, the lab performs specific tests on the biopsy tissue. The two main tests, as described by MedlinePlus and Mayo Clinic, are: * **Immunohistochemistry (IHC):** This test measures the amount of HER2 protein on the surface of the cancer cells. Results are scored from 0 to 3+. A score of 3+ typically indicates HER2-positive cancer. * **Fluorescence in situ hybridization (FISH):** If IHC results are unclear (e.g., 2+), or sometimes as a primary test, FISH is used. This test counts the number of HER2 gene copies inside the cancer cells. Having too many copies of the HER2 gene indicates HER2-positive cancer. These tests are crucial because the HER2 status guides treatment decisions. Knowing whether the cancer is HER2-positive allows doctors to recommend targeted therapies specifically designed to block the HER2 protein, which are highly effective for this type of breast cancer.

Treatment options

Treatment for HER2-positive breast cancer often involves a combination of therapies, with a strong emphasis on targeted drugs that specifically block the HER2 protein. These targeted therapies are usually given alongside chemotherapy, and may also include surgery, radiation therapy, and hormone therapy if the cancer is also hormone receptor-positive.

The primary treatment approach for HER2-positive breast cancer focuses on targeted therapies. These drugs work by attaching to the HER2 protein on cancer cells, blocking their growth signals and sometimes marking them for destruction by the immune system. According to MedlinePlus and Mayo Clinic, common targeted therapies include: * **Trastuzumab (Herceptin):** Often given with chemotherapy, it can be used before or after surgery, and for metastatic disease. * **Pertuzumab (Perjeta):** Also used with trastuzumab and chemotherapy, particularly for early-stage or metastatic HER2-positive breast cancer. * **Ado-trastuzumab emtansine (Kadcyla or T-DM1):** A drug that combines trastuzumab with a chemotherapy drug, delivering chemotherapy directly to HER2-positive cells. * **Fam-trastuzumab deruxtecan-nxki (Enhertu):** Another antibody-drug conjugate used for advanced HER2-positive breast cancer. * **Lapatinib (Tykerb) and Neratinib (Nerlynx):** Oral targeted therapies that can be used in certain situations, often for advanced disease or after initial treatments. Chemotherapy is almost always part of the treatment plan for HER2-positive breast cancer, often given before (neoadjuvant) or after (adjuvant) surgery. Surgery, such as a lumpectomy (removing the tumor and some surrounding tissue) or mastectomy (removing the entire breast), is typically performed to remove the primary tumor. Radiation therapy may follow surgery to destroy any remaining cancer cells in the breast area. If the cancer cells also have hormone receptors (meaning they are hormone receptor-positive and HER2-positive), hormone therapy may be added to the treatment regimen. The specific combination and sequence of treatments will depend on the cancer's stage, size, and whether it has spread, as well as the individual's overall health and preferences. The Cochrane Library highlights the effectiveness of these targeted therapies in improving outcomes.

Recovery & outlook

The recovery and outlook for people with HER2-positive breast cancer have significantly improved due to advancements in targeted therapies. While historically considered more aggressive, these cancers now often have a good prognosis, especially when detected early and treated with specific HER2-blocking drugs. Regular follow-up care is essential after treatment.

Before the development of HER2-targeted therapies, HER2-positive breast cancer was associated with a higher risk of recurrence and a poorer outlook compared to other breast cancer types. However, the introduction of drugs like trastuzumab and others has revolutionized treatment, leading to much better outcomes. Today, many people with HER2-positive breast cancer achieve long-term remission or are cured, particularly if the cancer is caught at an early stage. The specific outlook depends on several factors, including the stage of the cancer at diagnosis, the tumor's grade (how abnormal the cells look), whether lymph nodes are involved, and the individual's overall health and response to treatment. After completing initial treatment, ongoing monitoring is crucial. This typically involves regular physical exams, mammograms, and sometimes other imaging tests or blood tests. These follow-up appointments help detect any signs of recurrence early and manage potential long-term side effects of treatment. A healthy lifestyle, including a balanced diet and regular exercise, can also support overall well-being during recovery.

When to see a doctor

You should see a doctor promptly if you notice any new or unusual changes in your breasts, such as a new lump, swelling, skin changes, or nipple discharge. While many breast changes are not cancer, it is crucial to have them evaluated by a healthcare professional to ensure an accurate diagnosis and timely treatment if needed.

Early detection of breast cancer, including HER2-positive types, significantly improves treatment outcomes. Do not delay seeking medical advice if you experience any of the following: * A new lump or mass in your breast or armpit, even if it's painless. * Any change in the size or shape of your breast. * Dimpling, puckering, redness, scaling, or thickening of the breast skin. * Nipple changes, such as inversion (turning inward), redness, scaling, or any discharge other than breast milk. * Persistent pain in any part of your breast or nipple. It's important to remember that these symptoms do not automatically mean you have cancer, but they warrant a thorough medical evaluation. Your doctor can perform a physical exam and recommend further diagnostic tests, such as mammograms, ultrasounds, or biopsies, to determine the cause of your symptoms. Regular screening mammograms, as recommended by your doctor based on your age and risk factors, are also vital for detecting breast cancer before symptoms even appear.

Frequently asked questions

Is HER2-positive breast cancer more aggressive than other types?

Historically, HER2-positive breast cancer was considered more aggressive because the excess HER2 protein promotes faster cancer cell growth and spread. However, with the development of targeted therapies specifically designed to block HER2, the prognosis has significantly improved, and it is now often very treatable, especially when caught early.

Can HER2-positive breast cancer be cured?

Yes, HER2-positive breast cancer can be cured, especially when diagnosed at an early stage. Modern treatments, particularly targeted therapies combined with chemotherapy, surgery, and radiation, have greatly increased the chances of long-term remission and cure for many individuals.

Are there specific lifestyle changes that can help manage HER2-positive breast cancer?

While lifestyle changes cannot cure HER2-positive breast cancer, maintaining a healthy lifestyle can support overall well-being during and after treatment. This includes eating a balanced diet, engaging in regular physical activity, maintaining a healthy weight, and avoiding excessive alcohol consumption. Always discuss lifestyle changes with your healthcare team.

Does HER2-positive breast cancer run in families?

HER2-positive status refers to a characteristic of the cancer cells themselves, not an inherited condition. While a general family history of breast cancer can increase your overall risk of developing breast cancer, the HER2-positive status typically arises from genetic changes within the tumor cells during a person's lifetime and is not passed down through generations.

What is the difference between HER2-positive and hormone receptor-positive breast cancer?

HER2-positive refers to cancer cells having too much HER2 protein. Hormone receptor-positive means cancer cells have receptors for hormones like estrogen or progesterone, which can fuel their growth. A breast cancer can be HER2-positive, hormone receptor-positive, both, or neither. Treatment plans differ based on these specific characteristics.

How long do people typically receive HER2-targeted therapy?

The duration of HER2-targeted therapy varies depending on the specific drug, the stage of cancer, and individual response. For early-stage HER2-positive breast cancer, targeted therapy like trastuzumab is often given for about one year after surgery and chemotherapy. For advanced or metastatic disease, treatment may continue for a longer period as long as it is effective and well-tolerated.

Sources

• MedlinePlus — HER2-Positive Breast Cancer
• Mayo Clinic — HER2-Positive Breast Cancer
• Cochrane Library — HER2-Positive Breast Cancer